DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 11/18/2019 --Hypoactive Sexual Desire Disorder Market Insights, Epidemiology, and Market Forecast- 2028

1. About one in ten women have Hypoactive Sexual Desire Disorder, making it one of the most common female sexual difficulties.
2. A greater proportion of surgically menopausal women had low sexual desire compared with premenopausal or naturally menopausal women.
3. A proportion of European women with low desire increased from approximately 10% amongst women in their twenties to nearly 50% amongst women aged older age group.

(Albany, US) DelveInsight launched a new report on Hypoactive Sexual Desire Disorder Market Insights, Epidemiology and Market Forecast-2028

Key benefits
1. Hypoactive Sexual Desire Disorder market report covers a descriptive overview and comprehensive insight of the Hypoactive Sexual Desire Disorder epidemiology and Hypoactive Sexual Desire Disorder market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Hypoactive Sexual Desire Disorder market report provides insights into current and emerging therapies.
3. Hypoactive Sexual Desire Disorder market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Hypoactive Sexual Desire Disorder market report offers an edge that will help in developing business strategies by understanding trends shaping and leading the Hypoactive Sexual Desire Disorder market.

Request for sample pages

"The lack of interest in sex for women in the US has been observed to be higher in middle-aged women, i.e. 30-39 and lowest in women aged between 50-59 and 8-29."

Hypoactive Sexual Desire Disorder (HSDD) is a condition where various factors like physical condition and psychological factors lead to a persistent lack of libido. This condition affects both genders, but various studies have shown that women are profoundly affected by this disorder. The disease can be diagnosed as being situational; symptoms are only present with certain types of stimulation, situations, or partners. Hypoactive Sexual Desire Disorder Treatment involves sex therapy, psychotherapy, pharmacological therapies, and hormonal treatment regimens.

Various studies of testosterone therapy in women with low desire after surgical menopause have demonstrated significant increases in libido and sexual satisfaction in women on estrogen and decrease personal distress. Both naturally and surgically menopausal women, not on estrogen replacement, have shown similar benefits from testosterone therapy. However, the role of androgens remains controversial, with side effects like increased hair growth in women. Besides these treatment regimens, various drugs are also recommended off-label for the Hypoactive Sexual Desire Disorder treatment, such as Buropion, Sildenafil, and Busopirone.

The dynamics of Hypoactive Sexual Desire Disorder market is expected to change in the upcoming years due to the improvement in the diagnostic methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also anticipates the launch of emerging therapies during the forecast period of 2019-2028.

The launch of the emerging therapies is expected to significantly impact Hypoactive Sexual Desire Disorder treatment scenario in the upcoming years: -
Drugs covered
1. BP101
2. And many others

The key players in the Hypoactive Sexual Desire Disorder market are:
1. Ivix LLX
2. EndoCeutics
3. Acerus Pharma
4. Pivot Pharma
And many others

Table of contents
1. Report Introduction
2. Hypoactive Sexual Desire Disorder Market Overview at a Glance
3. Hypoactive Sexual Desire Disorder Disease Background and Overview
4. Hypoactive Sexual Desire Disorder Epidemiology and Patient Population
5. Hypoactive Sexual Desire Disorder Epidemiology by Countries (2017-2028)
5.1. United States- Epidemiology (2017-2028)
5.2. EU-5 - Epidemiology (2017-2028)
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
6. Hypoactive Sexual Desire Disorder Treatments & Medical Practices
7. Hypoactive Sexual Desire Disorder Marketed Product
8. Addyi (Flibanserin; Sprout Pharmaceuticals)
9. Vyleesi (Palatin Technologies/Amag Pharmaceuticals)
10. Hypoactive Sexual Desire Disorder Emerging Therapies
10.1. Key Cross Competition
10.2. BP101 (Ivix LLX)
11. Hypoactive Sexual Desire Disorder Market Size
12. 7MM: Country-Wise Market Analysis
12.1. United States Market Size
12.2. Germany Market Size
12.3. France Market Size
12.4. Italy Market Size
12.5. Spain Market Size
12.6. United Kingdom Market size
12.7. Japan Market Size
13. Market Drivers
14. Market Barriers
15. Hypoactive Sexual Desire Disorder Report Methodology
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.